• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Shineco Inc.

    7/12/24 5:28:03 PM ET
    $SISI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SISI alert in real time by email
    SC 13D 1 formsc13d.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    SHINECO, INC.

    (Name of Issuer)

     

    COMMON STOCK, PAR VALUE $0.001 PER SHARE

    (Title of Class of Securities)

     

    824567408

    (CUSIP Number)

     

    Shanchun Huang

    Flat 111 Coleherne Court

    Old Brompton Road, London SW5 0ED

    Tel: +447999 688888

     

    (Name, Address and Telephone Number of Person Authorized to

    Receive Notices and Communications)

     

    July 8, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 824567408

     

    1

    NAMES OF REPORTING PERSONS

     

    Shanchun Huang

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS (See Instructions)

     

    PF

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

    PURSUANT TO ITEMS 2(d) or 2(e)                   ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Malta

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

     

    7

    SOLE VOTING POWER

     

    1,248,924

    8

    SHARED VOTING POWER

     

    n/a

    9

    SOLE DISPOSITIVE POWER

     

    1,248,924

    10

    SHARED DISPOSITIVE POWER

     

    n/a

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,248,924

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ☐
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    13.3%(1)

    14

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN

     

    (1) This percentage is calculated based upon 9,373,165 shares of the Issuer’s common stock issued and outstanding as of July 9, 2024.

     

     
     

     

    CUSIP No. 824567408

     

    Item 1. Security and Issuer.

     

    This Schedule 13D relates to the common stock par value $0.001 per share (the “Common Stock”) of Shineco, Inc., a Delaware Corporation (the “Issuer”). The address of the principal executive offices of the Issuer is T1, South Tower, Jiazhaoye Square, Chaoyang District, Beijing, People’s Republic of China 100022.

     

    Item 2. Identity and Background.

     

    a) Name:

     

    This statement is filed by Shanchun Huang, a Malta citizen (the “Reporting Person”).

     

    (b) Residence or business address:

     

    The principal mailing address of the Reporting Person is Flat 111 Coleherne Court, Old Brompton Road London SW5 0ED.

     

    (c) Principal business of each reporting person and address:

     

    The principal business of the Reporting Person is investment.

     

    Address: Flat 111 Coleherne Court, Old Brompton Road, London SW5 0ED

     

    (d) — (e) During the last five years, the Reporting Person has not been: (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f) The Reporting Person is a citizen of the Republic of Malta.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    All shares of Common Stock were purchased with the Reporting Person’s personal funds. The total amount of the funds used to make the purchases described in Item 4 was $5,000,000.

     

    Item 4. Purpose of Transaction.

     

    (a)-(j) On June 20, 2024, the Issuer entered into a securities purchase agreement (the “Purchase Agreement”) with the Reporting Person, pursuant to which the Issuer sold and issued to the Reporting Person 1,000,000 shares of Common Stock at a price of $ 5.00 per share on July 8, 2024.

     

    The Reporting Person acquired all of his shares of the Issuer’s Common Stock for investment purposes. The Reporting Person believes the securities of the Issuer represent an attractive investment opportunity.

     

    The Reporting Person has had and anticipates having further discussions with officers and directors of the Issuer in connection with the Reporting Person’s investment in the Issuer. The topics of these conversations will cover a range of issues, including those relating to the business, management, operations, capital allocation, asset allocation, capital and corporate structure, distribution policy, financial condition, mergers and acquisitions strategy, overall business strategy, executive compensation, and corporate governance. The Reporting Person may also communicate with other shareholders or interested parties, such as industry analysts, existing or potential strategic partners or competitors, investment professionals, and other investors. The Reporting Person may at any time reconsider and change his intentions relating to the foregoing. The Reporting Person may also take one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D and may discuss such actions with the Issuer’s management, other shareholders of the Issuer, and other interested parties, such as those set out above.

     

    The Reporting Person intends to review his investments in the Issuer on a continuing basis. Depending on various factors, including, without limitation, the Issuer’s financial positions and strategic direction, the outcome of the discussions and actions referenced above, actions taken by the board of directors, price levels of the Common Stock, other investment opportunities available to the Reporting Person, tax implications, conditions in the securities market and general economic and industry conditions, the Reporting Person may in the future take actions with respect to its investment position in the Issuer as it deems appropriate, including, without limitation, purchasing additional Common Stock or other instruments that are based upon or relating to the value of the Common Stock or the Issuer in the open market or otherwise, selling some or all of the interest in the Issuer held by the Reporting Person, and/or engaging in hedging or similar transactions with respect to the Common Stock.

     

     
     

     

    CUSIP No. 824567408

     

    The Reporting Person is an affiliate of the Issuer and intends to continue to take an active role in the Issuer’s management and strategic direction.

     

    There can be no assurance that the Reporting Person will pursue any of the matters set forth above. Moreover, there can be no assurance that the Reporting Person will or will not develop any plans or proposals with respect to any of the foregoing matters or take any particular action or actions with respect to some or all of his holdings in the Issuer, or as to the timing of any such matters should they be so pursued by the Reporting Person. The Reporting Person reserve the right, at any time and in Reporting Person’s sole discretion, to take or refrain from taking any of the actions set forth above.

     

    Except as described in this Item 4, as of the date of this statement the Reporting Person has no present plan or proposal that relates to or would result in any of the matters set forth in subsections (a) through (j) of Item 4 of Schedule 13D.

     

    Item 5. Interest in Securities of the Issuer.

     

    (a) The Reporting Person owns an aggregate of 1,248,924 shares of the Issuer’s Common Stock. Based upon 9,373,165 shares of the Issuer’s common stock outstanding as of July 9, 2024, the shares of the Issuer’s Common Stock beneficially owned by the Reporting Person constitute approximately 13.3% of the Common Stock of the Issuer as calculated in accordance with Rule 13d-3(d)(1).

     

    (b) Mr. Huang may be deemed to hold sole voting and dispositive power over 1,248,924 shares of common stock of the Issuer.

     

    (c) To the best knowledge of the Reporting Person, except as set forth in this Schedule 13D, the Reporting Person has not effected any other transactions in any securities of the Issuer in the past 60 days.

     

    (d) To the best knowledge of the Reporting Person, except as set forth in this Schedule 13D, no person other than the Reporting Person has the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of the shares of Common Stock reported in Item 5(a).

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    Other than as described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities.

     

    Item 7. Material to be Filed as Exhibits.

     

    Exhibit No.

     

    Description

    10.1   Securities Purchase Agreement dated June 20, 2024, by and between the Issuer and the Reporting Person (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K, filed with the SEC on June 21, 2024)

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: July 12, 2024  
       
    /s/ Shanchun Huang  
    Shanchun Huang  

     

     

     

    Get the next $SISI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SISI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SISI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company

      Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ((", Shineco", or the ", Company", , NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a company incorporated under the laws of Hong Kong that has been wholly owned held by Dr. Lim ("InfiniClone"). InfiniClone is a biotechnology company focusing on the field of re

      4/23/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Acquisition of Medical Device Company

      The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business  BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited ("Shineco Life Science"), a subsidiary of the Company, entered into a Stock Purchase Agreement ("SPA") with Yi Yang (the "Seller"), for 75% of an equity interest in FuWang (HK) International Company Limited ("FuWang Company"). The Seller is the current and only shareholder of FuWang Company, which specializes i

      3/25/25 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces Reverse Split to Regain NASDAQ Compliance

      BEIJING, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that effective at 12:01 a.m., EDT, on November 12, 2024, the Company will effect a one-for-twenty four (1-for-24) reverse stock split of its outstanding common stock (the "Reverse Stock Split"). The Reverse Stock Split is primarily intended to bring the Company into compliance with the minimum average closing share price requirement for maintaining its listing on the Nasdaq Capital Market. The Company's common stock will continue to trade under the symbol "SISI". Upon the effectiveness of the R

      11/12/24 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Leadership Updates

    Live Leadership Updates

    See more
    • Future FinTech Announces the Appointment of Hu Li as the New CEO

      NEW YORK, Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024. Mr. Li will be fully responsible for the operation and management of the Company, helping it to expand internationally, manage its investment and financi

      8/9/24 9:00:00 AM ET
      $FTFT
      $SISI
      Business Services
      Consumer Discretionary
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Announces the Appointment of Two New Executive Officers

      BEIJING, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a provider of technologically advanced healthcare products and services, announced today that its Board of Directors has appointed Ms. Xiaohui Wang and Mr. Chi Keung Yan as executive officers of the Company in key leadership roles. Effective November 13, 2023, Shineco's Board of Directors appointed Ms. Xiaohui Wang as Executive President of the Company. From March 2000 to November 2013, Ms. Wang was the founder and Chairperson of Chongqing Wintus (New Star) Enterprises Group, where she was responsible for its corporate planning, supervision of the group's business in the Chongqing region,

      11/17/23 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco, Inc. Appoints Professor Qiyin Sun as Chief Medical Consultant

      BEIJING, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Shineco, Inc. (("Shineco" or the "Company", NASDAQ:SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that the Company has appointed Professor Qiyin Sun as the Chief Medical Consultant. Professor Sun will lead the research and innovation of the Company's tumor treatment and provide technical consultation in early tumor screening and tumor radiotherapy to support the commercialization of digital tumor diagnosis and treatment. Prior to serving as the chief medical consultant at Shineco, Professor Sun was a director at Beijing Nuclear Medicine Equipment Engineering Technology R

      2/1/22 9:00:00 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Shineco Inc.

      SC 13G/A - SHINECO, INC. (0001300734) (Subject)

      10/25/24 2:45:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Shineco Inc.

      SC 13D - SHINECO, INC. (0001300734) (Subject)

      7/12/24 5:28:03 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Shineco Inc.

      SC 13G - SHINECO, INC. (0001300734) (Subject)

      8/29/23 1:26:38 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    SEC Filings

    See more
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      4/23/25 9:00:37 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • Shineco Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - SHINECO, INC. (0001300734) (Filer)

      3/20/25 2:30:26 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by Shineco Inc.

      EFFECT - SHINECO, INC. (0001300734) (Filer)

      3/20/25 12:15:03 AM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care

    $SISI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huang Shanchun claimed ownership of 5,041,667 shares (SEC Form 3)

      3 - SHINECO, INC. (0001300734) (Issuer)

      4/24/25 4:05:15 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Yan Chi Keung

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:17 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Wang Xiaohui

      3 - SHINECO, INC. (0001300734) (Issuer)

      12/7/23 4:10:16 PM ET
      $SISI
      Medicinal Chemicals and Botanical Products
      Health Care